Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized Controlled, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Rocbrutinib Monotherapy Versus Investigator's Choice of Therapy in Patients With Relapsed or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

NCT07189065 is registered in ClinicalTrials.gov with Guangzhou Lupeng Pharmaceutical Company LTD. as lead sponsor.

NCT NCT07189065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized Controlled, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Rocbrutinib Monotherapy Versus Investigator's Choice of Therapy in Patients With Relapsed or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Lead sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase
Phase 2
Overall status
Recruiting
Start date
November 27, 2025
Completion date
December 31, 2028
Enrollment
150 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl)